Recent Quotes
My Watchlist
Indicators
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries

News releases from Aptorum Group Limited

Aptorum Group Receives Clearance from Health Canada to Initiate a Phase 1 Clinical Trial for ALS-4, a Small Molecule Drug for Infections Caused by Staphylococcus aureus including Methicillin-resistant
Aptorum Group Limited (Nasdaq: APM, Euronext Paris: APM) ) (“Aptorum Group” or “Aptorum”), a biopharmaceutical company focused on novel technologies including the targeting of infectious diseases,... 
Tickers APM
From Business Wire News Releases
Aptorum Group Announces Submission of Clinical Trial Application for ALS-4, an Orally Administered Small Molecule Drug for the Treatment of Infections caused by Staphylococcus aureus including Methici
Regulatory News: 
Tickers APM
From Business Wire News Releases
Aptorum Group Limited Announces Results of 2020 Annual General Meeting of Shareholders
Regulatory News: 
Tickers APM
From Business Wire News Releases
Aptorum Group Limited to Hold Annual General Meeting of Shareholders on December 9, 2020
Regulatory News: 
Tickers APM
From Business Wire News Releases
Aptorum Group Announces Closing of $9.0 Million Public Offering
Aptorum Group Limited (Nasdaq:APM, Euronext Paris:APM) (“Aptorum Group” or “Aptorum”), a biopharmaceutical company focused on novel technologies including the targeting of infectious diseases, today... 
Tickers APM
From Business Wire News Releases
Aptorum Group Announces Pricing of $9.0 Million Public Offering
Regulatory News: 
Tickers APM
From Business Wire News Releases
Aptorum Group Launches Infectious Disease Liquid Biopsy Subsidiary Start-up and Exclusively In-licensed from Singapore based Accelerate Technologies To Co-Develop Molecular Based Rapid Pathogen Diagno
Regulatory News: 
Tickers APM
From Business Wire News Releases
Aptorum Group to Hold Investor Webinar and Present at The Wall Street Investor Forum on September 10
Aptorum Group Limited (Nasdaq: APM, Euronext Paris: APM) (“Aptorum Group” or “Aptorum”), a biopharmaceutical company focused on novel therapeutics including the development of next-generation approach... 
Tickers APM
From Business Wire News Releases
Aptorum Group Joins the BEAM Alliance To Combat Antimicrobial Resistance
Aptorum Group Limited (Nasdaq: APM, Euronext Paris: APM) (“Aptorum Group”), a biopharmaceutical company focused on novel therapeutics including the development of next-generation therapeutics targeting... 
Tickers APM
From Business Wire News Releases
Aptorum Group Announces Video Update Discussing Positive Data on SACT-1 Against Neuroblastoma and Other Potential Tumor Types
Aptorum Group Limited (NASDAQ: APM, Euronext Paris: APM) (“Aptorum Group”), a biopharmaceutical company focused on novel therapeutics including the development of next-generation approach therapeutics... 
Tickers APM
From Business Wire News Releases
Aptorum Group Limited Reports Financial Results and Business Update for the Six Months Ended June 30, 2020
Aptorum Group Limited (NASDAQ: APM, Euronext Paris: APM) (“Aptorum Group” or the “Company”), a biopharmaceutical company focuses on the development of novel therapeutics to address global unmet medical... 
Tickers APM
From Business Wire News Releases
Aptorum Group Announces Further Positive Data on ALS-4 against MRSA Wound Infection and MRSA Bacteraemia against Linezolid and Vancomycin Respectively in In Vivo Models
Aptorum Group Limited (NASDAQ: APM, Euronext Paris: APM) (“Aptorum Group”), a biopharmaceutical company focused on novel therapeutics including the development of next-generation approach therapeutics... 
Tickers APM
From Business Wire News Releases
Aptorum Group Interview to Air on Bloomberg International on the RedChip Money Report
Regulatory News: 
Tickers APM
From Business Wire News Releases
Aptorum Group Limited to Present at The LD 500 Virtual Conference and H.C. Wainwright 22nd Annual Global Life Sciences Conference
Regulatory News: 
Tickers APM
From Business Wire News Releases
Aptorum Group Appoints Dr. Herman Weiss as CEO of microbiome-based platform Claves Life Sciences and Dr. Robbie Majzner as scientific advisor to SACT-1 drug for Neuroblastoma and others
Regulatory News: 
Tickers APM CTLT
From Business Wire News Releases
Aptorum Group Becomes the First Nasdaq Listed Biopharmaceutical Company Admitted to Trading on Euronext Paris Stock Exchange Under the Ticker Symbol APM
Regulatory News: 
Tickers APM
From Business Wire News Releases
Aptorum Group Prospectus Receives Approval for Listing on the Euronext Paris Stock Exchange
Regulatory News: 
Tickers APM
From Business Wire News Releases
Aptorum Group Limited Strengthens Its Presence in the US With the Appointment of Dr. Kira Sheinerman
Aptorum Group Limited (NASDAQ:APM), a biopharmaceutical company focused on the development of novel therapeutics to address global unmet medical needs, today announced the appointment of Dr. Kira... 
Tickers APM
From Business Wire News Releases
Aptorum Group Interview to Air on Bloomberg International on the RedChip Money Report
Aptorum Group Limited (NASDAQ:APM), a biopharmaceutical company focused on the development of novel therapeutics to address global unmet medical needs, today announced an interview with its President,... 
Tickers APM
From Business Wire News Releases
Aptorum Group to Hold Investor Webinar and Q&A Session with President on May 19
Aptorum Group Limited (NASDAQ:APM), a biopharmaceutical company focused on the development of novel therapeutics to address global unmet medical needs, today announced President and Executive Director... 
Tickers APM
From Business Wire News Releases
Aptorum Group Limited to Present at the Infectious Disease Virtual Conference
Aptorum Group Limited (Nasdaq:APM) (“Aptorum Group”), a biopharmaceutical company focused on the development of novel therapeutics to address global unmet medical needs, including orphan diseases,... 
Tickers APM
From Business Wire News Releases
Aptorum Group Limited Reports 2019 Fiscal Year End Financial Results and Provides Business Update
Aptorum Group Limited (NASDAQ:APM), a biopharmaceutical company focused on the development of novel therapeutics to address global unmet medical needs, today announced financial results for the fiscal... 
Tickers APM
From Business Wire News Releases
Aptorum Group Limited Corporate Update and To Hold Q1 2020 Investor Update Call To Discuss Recent Development and Pipeline Progress
Aptorum Group Limited (Nasdaq: APM) (“Aptorum Group”), a biopharmaceutical company focused on the development of novel therapeutics to address global unmet medical needs, today provides an update on... 
Tickers APM
From Business Wire News Releases
Aptorum Group Collaborates with Covar Pharmaceuticals To Investigate at Least 3 Repurposed Drug Candidates (SACT-COV19) for Coronavirus Disease 2019 (COVID-19) under Existing Smart-ACT™ Platform and A
Aptorum Group Limited (Nasdaq: APM) ("Aptorum Group"), a biopharmaceutical company focused on the development of novel therapeutics for unmet needs including but not limited to infectious, orphan and... 
Tickers APM
From Business Wire News Releases
Aptorum Group Limited to Present at the Solebury Trout Virtual Investor Conference
Aptorum Group Limited (NASDAQ:APM) (“Aptorum Group”), a biopharmaceutical company focused on the development of novel therapeutics to address global unmet medical needs, today announced that Ian Huen,... 
Tickers APM
From Business Wire News Releases
Aptorum Group Announces Closing of $10 Million Registered Direct Offering of Class A Ordinary Shares and Warrants
Aptorum Group Limited (NASDAQ:APM) (“Aptorum Group”), a biopharmaceutical company focused on the development of novel therapeutics to address global unmet medical needs, today announced the closing of... 
Tickers APM
From Business Wire News Releases
Aptorum Group Announces Pricing of $10 Million Registered Direct Offering
Aptorum Group Limited (NASDAQ: APM) (“Aptorum Group”), a biopharmaceutical company focused on the development of novel therapeutics to address global unmet medical needs, today announced the pricing of... 
Tickers APM
From Business Wire News Releases
Aptorum Group Commences Commercialization of Dioscorea Opposita Bioactive Nutraceutical Tablets and Signed Sales Distribution Agreement in Hong Kong
Aptorum Group Limited (“Aptorum Group”), a pharmaceutical company focused on the development of novel therapeutics to address global unmet medical needs, announces the commercialization of its dietary... 
Tickers APM
From Business Wire News Releases
Aptorum Group Announces Further Positive Data For Its ALS-4 Small Molecule Anti-virulence (Non-bactericidal) Drug Candidate For The Treatment of Infections Caused By Staphylococcus Aureus and On Track
Aptorum Group Limited (NASDAQ: APM) (“Aptorum Group”), a biopharmaceutical company focused on the development of novel therapeutics to address global unmet medical needs, announces further positive... 
Tickers APM
From Business Wire News Releases
Aptorum Group Announces Significant Progress of Repurposed Drug Candidate, SACT-1 for Neuroblastoma Targeting IND Submission in H2 2020
Aptorum Group Limited (Nasdaq: APM) (“Aptorum Group”), a biopharmaceutical company focused on the development of novel therapeutics to address global unmet medical needs, announces positive data and... 
Tickers APM
From Business Wire News Releases
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.